FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.

Saved in:
Bibliographic Details
Title: FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.
Authors: Stintzing S; Department of Hematology, Oncology, and Cancer Immunology (CCM), Charité-Universitaetsmedizin Berlin, Germany.; German Cancer Consortium (DKTK), partner site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany., Heinrich K; Department of Oncology, LMU University Hospital, Munich, Germany., Tougeron D; Department of Hepato-Gastroenterology, Poitiers University Hospital and University of Poitiers, Poitiers, France., Modest DP; Department of Hematology, Oncology, and Cancer Immunology (CCM), Charité-Universitaetsmedizin Berlin, Germany., Schwaner I; Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany., Eucker J; Department of Hematology, Oncology, and Cancer Immunology (CBF), Charité-Universitaetsmedizin Berlin, Germany., Pihusch R; MVZ Praxis Pihusch, Rosenheim, Germany., Stauch M; Hematology, Oncology/Hemostaseology Kronach, Kronach, Germany., Kaiser F; VK&K Oncology GmbH, Landshut, Germany., Kahl C; Klinikum Magdeburg gGmbH, Department of Hematology, Oncology and Palliative Care Magdeburg, Germany.; Department of Internal Medicine, Clinic III-Hematology, Oncology and Palliative Care, Rostock University Medical Center, Rostock, Germany., Karthaus M; Department of Hematology, Oncology and Palliative Care, München Klinik Harlaching and Neuperlach, Munich, Germany., Müller C; Evang. Kliniken Essen-Mitte, Essen, Germany., Burkart C; Schwarzwald-Baar Klinikum Villingen-Schwenningen, Germany., Reinacher-Schick A; Department of Hematology, Oncology and Palliative Care, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany., Kasper-Virchow S; West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, Germany., Fischer von Weikersthal L; Gesundheitszentrum St Marien, Amberg, Germany., Krammer-Steiner B; Department of Hematology and Oncology; Klinikum Rostock Südstadt, Rostock, Germany., Prager GW; Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria., Taieb J; Department of Hepato-Gastroenterology, Poitiers University Hospital and University of Poitiers, Poitiers, France.; Department of Gastroenterology and GI Oncology, University Paris-Cité, (Paris Descartes), SIRC CARPEM, Hopital Européen Georges Pompidou, Paris, France., Heinemann V; Department of Oncology, LMU University Hospital, Munich, Germany.; Department of Gastroenterology and GI Oncology, University Paris-Cité, (Paris Descartes), SIRC CARPEM, Hopital Européen Georges Pompidou, Paris, France.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Sep 01; Vol. 41 (25), pp. 4143-4153. Date of Electronic Publication: 2023 Jun 23.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO.22.01420